Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma

被引：0
|
作者：
Chai, C. S. [1 ]
Liam, C. K. [2 ]
Pang, Y. K. [2 ]
Kow, K. S. [2 ]
Wong, C. K. [2 ]
Poh, M. E. [2 ]
Tan, J. L. [2 ]
机构：
[1] Univ Malaysia Sarawak, Fac Med & Hlth Sci, Dept Med, Kota Samarahan, Malaysia
[2] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur, Malaysia
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
470P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
    Chen, Po-Yen
    Wang, Chin-Chou
    Hsu, Chien-Ning
    Chen, Chung-Yu
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [2] Hepatoid Adenocarcinoma of the Lung With EGFR Mutation and the Response to Tyrosine Kinase Inhibitor
    Chen, H.
    Wang, W.
    Li, X.
    Xu, C.
    Zhu, Y.
    Du, K.
    Fang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S585 - S585
  • [3] Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor
    Watanabe, Kousuke
    Yasumoto, Atsushi
    Amano, Yosuke
    Kage, Hidenori
    Goto, Yasushi
    Yatomi, Yutaka
    Takai, Daiya
    Nagase, Takahide
    PLOS ONE, 2018, 13 (09):
  • [4] Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors
    Chen, Hua-fei
    Wang, Wen-xian
    Li, Xing-liang
    Xu, Chun-wei
    Du, Kai-qi
    Zhu, You-cai
    Fang, Mei-yu
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E217 - E219
  • [5] Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
    Tatsuya Yoshida
    Genichiro Ishii
    Koichi Goto
    Kiyotaka Yoh
    Seiji Niho
    Shigeki Umemura
    Shingo Matsumoto
    Hironobu Ohmatsu
    Kanji Nagai
    Yuichiro Ohe
    Atsushi Ochiai
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1691 - 1700
  • [6] Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
    Yoshida, Tatsuya
    Ishii, Genichiro
    Goto, Koichi
    Yoh, Kiyotaka
    Niho, Seiji
    Umemura, Shigeki
    Matsumoto, Shingo
    Ohmatsu, Hironobu
    Nagai, Kanji
    Ohe, Yuichiro
    Ochiai, Atsushi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (10) : 1691 - 1700
  • [7] EGFR - TYROSINE KINASE INHIBITOR AS FIRST LINE TREATMENT IN METASTATIC LUNG ADENOCARCINOMA
    Febriani, Anna
    Wulandari, Laksmi
    Hariadi, Slamet
    Wibisono, Yusuf
    RESPIROLOGY, 2010, 15 : 67 - 67
  • [8] RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation
    Yoshida, Tatsuya
    Yoh, Kiyotaka
    Niho, Seiji
    Umemura, Shigeki
    Matsumoto, Shingo
    Ohmatsu, Hironobu
    Ohe, Yuichiro
    Goto, Koichi
    LUNG CANCER, 2015, 90 (03) : 477 - 483
  • [9] Predictive value of serum HGF for treatment response to EGFR tyrosine kinase inhibitor in patients with lung adenocarcinoma
    Kasahara, K.
    Arao, T.
    Sakai, K.
    Sakai, A.
    Sone, T.
    Nishio, M.
    Ohira, T.
    Ikeda, N.
    Yamanaka, T.
    Nishio, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
    Rintaro Noro
    Masahiro Seike
    Fenfei Zou
    Chie Soeno
    Kuniko Matsuda
    Teppei Sugano
    Nobuhiko Nishijima
    Masaru Matsumoto
    Kazuhiro Kitamura
    Seiji Kosaihira
    Yuji Minegishi
    Akinobu Yoshimura
    Kaoru Kubota
    Akihiko Gemma
    BMC Cancer, 15
12345